{"chebi_id":"49668","chebi_name":"gefitinib","chebi_synonyms":["N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine","N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine","ZD 1839","g\u00e9fitinib","4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline","Iressa","ZD1839","Irressat","ZD-1839","gefitinibum"],"diffprof_id_observed":["MTBLS5195_0002_00000001"],"diffprof_id_var_observed":[],"inchikey":"XGALLCVXEZPNRQ-UHFFFAOYSA-N","inn_name":"g\u00e9fitinib","iupac_name":"<em>N</em>-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine","num_study_observed":1,"reactome_ids":["R-HSA-1227990","R-HSA-1236382","R-HSA-1643685","R-HSA-1643713","R-HSA-5637815","R-HSA-5663202","R-HSA-9664565"],"reactome_names":["Signaling by ERBB2 in Cancer","Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants","Disease","Signaling by EGFR in Cancer","Signaling by Ligand-Responsive EGFR Variants in Cancer","Diseases of signal transduction by growth factor receptors and second messengers","Signaling by ERBB2 KD Mutants"],"study_id_observed":["MTBLS5195"],"study_id_var_observed":[],"synonym_name":"<em>N</em>-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine"}